Post Profile






MORGAN STANLEY: Here are the 10 healthcare companies most likely to get bought this year

It's shaping up to be a big year for healthcare M&A. In the month of January alone, there was a total of $27.5 billion worth of deals, including a $9 billion deal for a cancer drugmaker and a bidding war for a Belgian biotech. US tax reform has freed up a lot of cash companies had overseas — cash that might be spent on more acquisitions to boost their businesses. While it's easy to determine who might be in the mood to do some acquiring, spotting the targets can be a bit more difficult.
read more

share

Related Posts


Medivation just rejected Sanofi's $9.3 billion takeover bid (MDVN, SNY)

Business & Finance : Business Insider: Clusterstock

One of the bids for a San Francisco biotech has already fallen flat. On Friday, cancer drugmaker Medivation rejected pharma giant Sanofi's $9.3 billion takeover offer. The Sanofi bid was one of three major healthcare acquisitions th...

Celgene is buying cancer drugmaker Juno Therapeutics for $9 billion (CELG, JUNO)

Business & Finance : Business Insider: Clusterstock

Celgene is acquiring Juno Therapeutics, a company developing personalized cancer treatments in a deal worth $9 billion. It's be the second in 2018 for the biotech giant, which has been under pressure from investors. The highly perso...

Novo Nordisk got beat out on one of the first big healthcare deals of the year — here's what the CEO is still looking for in an acquisition (NVO)

Business & Finance : Business Insider: Clusterstock

Novo Nordisk in January came out with a $3.1 billion bid for Belgian biotech Ablynx, one of the first signs of M&A in a now-busy year. Novo was ultimately beaten out by rival Sanofi, which acquired Ablynx for $4.8 billion. Novo CEO ...

Two drug companies are exploding after a pair of biotech mega-deals (BIVV, JUNO)

Business & Finance : Business Insider: Clusterstock

French drugmaker Sanofi is acquiring biotech company Bioverativ in a $11.6 billion deal. Celgene is acquiring Juno Therapeutics, a company developing personalized cancer treatments, in a deal worth $9 billion. Both stocks are up big...

Regeneron’s coming late to a group of drugs that’s already worth billions — here’s why the company thinks it can still compete (REGN)

Business & Finance : Business Insider: Clusterstock

Biotech giant Regeneron has a cancer drug in the works that could be a very big deal. The drug, cemiplimab, is a checkpoint inhibitor, a kind of drug that's part of a new class of cancer medications known as immunotherapy.  There ar...

Comments


Copyright © 2016 Regator, LLC